{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:12:39Z","timestamp":1790611959877,"version":"4.1.0"},"reference-count":75,"publisher":"Societatea Romana de Morfologie","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rom J Morphol Embryol"],"published-print":{"date-parts":[[2025,5,23]]},"abstract":"<jats:p>Background\/Objectives: Ovarian neoplasms are the third most common gynecological cancer and carry a poorer prognosis than breast cancer. Endometrioid borderline ovarian tumors (EBOTs) are intermediate epithelial lesions, histologically showing glandular patterns with mild to moderate atypia and no stromal invasion. Study selection for review: A comprehensive electronic search was conducted on PubMed to identify risk factors and etiological determinants associated with ovarian endometrioid adenofibroma (EA). Case presentation: A 27-year-old woman with a left ovarian cyst underwent a laparoscopic procedure to remove the adnexa after imaging showed a 6 cm mass. Surgery was successful, and she was discharged without complications. Conclusions: This study highlights the diagnostic challenges of EBOTs, the essential role of immunohistochemistry, and the need for careful surgical and fertility-preserving strategies. It also draws attention to possible risks linked to fertility treatments. Fertility preservation is crucial in young patients, favoring uterine and ovarian conservation. In early-stage, small, non-invasive tumors, laparoscopy is the preferred approach. EAs are uncommon benign ovarian tumors, accounting for approximately 1% of epithelial neoplasms, and are predominantly unilateral.<\/jats:p>","DOI":"10.47162\/rjme.66.1.03","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T08:40:16Z","timestamp":1748594416000},"page":"39-49","source":"Crossref","is-referenced-by-count":12,"title":["Endometrioid adenofibroma of ovary \u2013 a literature review"],"prefix":"10.47162","volume":"66","author":[{"name":"Department of Surgery, University of Medicine and Pharmacy of Craiova, Romania; Department of Surgery, Railway Clinical Hospital, Craiova, Romania","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren\u0163iu Augustus","family":"Barbu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liviu","family":"Vasile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Surgery, University of Medicine and Pharmacy of Craiova, Romania; Department of Surgery, Emergency County Hospital, Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiberiu \u015etef\u0103ni\u0163\u0103","family":"\u0162enea-Cojan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Surgery, University of Medicine and Pharmacy of Craiova, Romania; Department of Surgery, Railway Clinical Hospital, Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Florin R\u0103zvan","family":"Mogo\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Surgery, University of Medicine and Pharmacy of Craiova, Romania; Department of Surgery, Railway Clinical Hospital, Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeriu","family":"\u015eurlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Surgery, University of Medicine and Pharmacy of Craiova, Romania; Department of Surgery, Emergency County Hospital, Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ionic\u0103 Daniel","family":"V\u00eelcea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Surgery, University of Medicine and Pharmacy of Craiova, Romania; Department of Surgery, Emergency County Hospital, Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Cercelaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Pathology, University of Medicine and Pharmacy of Craiova, Romania; Department of Pathology, Emergency County Hospital, Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stelian \u015etef\u0103ni\u0163\u0103","family":"Mogoant\u0103","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Surgery, University of Medicine and Pharmacy of Craiova, Romania; Department of Surgery, Emergency County Hospital, Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolae-Drago\u015f","family":"M\u0103rg\u0103ritescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Surgery, University of Medicine and Pharmacy of Craiova, Romania; Department of Surgery, Emergency County Hospital, Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26736","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"\"[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6):394-424. https:\/\/doi.org\/10.3322\/caac.21492. Erratum in: CA Cancer J Clin, 2020, 70(4):313. https:\/\/doi.org\/10.3322\/caac.21609","DOI":"10.3322\/caac.21609"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"[2] Yoneda A, Lendorf ME, Couchman JR, Multhaupt HAB. Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans. J Histochem Cytochem, 2012, 60(1):9-21. https:\/\/doi.org\/10.1369\/0022155411428469","DOI":"10.1369\/0022155411428469"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"[3] Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018. CA Cancer J Clin, 2018, 68(4):284-296. https:\/\/doi.org\/10.3322\/caac.21456","DOI":"10.3322\/caac.21456"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"[4] Hong MK, Ding DC. Early diagnosis of ovarian cancer: a comprehensive review of the advances, challenges, and future directions. Diagnostics (Basel), 2025, 15(4):406. https:\/\/doi.org\/10.3390\/diagnostics15040406","DOI":"10.3390\/diagnostics15040406"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"[5] Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med, 2017, 14(1):9-32. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2016.0084","DOI":"10.20892\/j.issn.2095-3941.2016.0084"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"[6] Moffitt L, Karimnia N, Stephens A, Bilandzic M. Therapeutic targeting of collective invasion in ovarian cancer. Int J Mol Sci, 2019, 20(6):1466. https:\/\/doi.org\/10.3390\/ijms20061466","DOI":"10.3390\/ijms20061466"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"[7] Bergsten TM, Burdette JE, Dean M. Fallopian tube initiation of high grade serous ovarian cancer and ovarian metastasis: mechanisms and therapeutic implications. Cancer Lett, 2020, 476:152-160. https:\/\/doi.org\/10.1016\/j.canlet.2020.02.017","DOI":"10.1016\/j.canlet.2020.02.017"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"[8] Hamilton W, Peters TJ, Bankhead C, Sharp D. Risk of ovarian cancer in women with symptoms in primary care: population based case-control study. BMJ, 2009, 339:b2998. https:\/\/doi.org\/10.1136\/bmj.b2998","DOI":"10.1136\/bmj.b2998"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"[9] Mohammadian M, Ghafari M, Khosravi B, Salehiniya H, Aryaie M, Bakeshei F, Mohammadian-Hafshejani A. Variations in the incidence and mortality of ovarian cancer and their relationship with the human development index in European countries in 2012. Biomed Res Ther, 2017, 4(8):1541-1557. https:\/\/doi.org\/10.15419\/bmrat.v4i08.228","DOI":"10.15419\/bmrat.v4i08.228"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"[10] Chan JK, Urban R, Cheung MK, Osann K, Shin JY, Husain A, Teng NN, Kapp DS, Berek JS, Leiserowitz GS. Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer, 2006, 95(10):1314-1320. https:\/\/doi.org\/10.1038\/sj.bjc.6603457. Erratum in: Br J Cancer, 2007, 96(3):534. Shin, J Y [added]. Erratum in: Br J Cancer, 2007, 96(9):1492.","DOI":"10.1038\/sj.bjc.6603457"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"[11] Poole EM, Merritt MA, Jordan SJ, Yang HP, Hankinson SE, Park Y, Rosner B, Webb PM, Cramer DW, Wentzensen N, Terry KL, Tworoger SS. Hormonal and reproductive risk factors for epithelial ovarian cancer by tumor aggressiveness. Cancer Epidemiol Biomarkers Prev, 2013, 22(3):429-437. https:\/\/doi.org\/10.1158\/1055-9965.EPI-12-1183-T","DOI":"10.1158\/1055-9965.EPI-12-1183-T"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"[12] Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health, 2019, 11:287-299. https:\/\/doi.org\/10.2147\/IJWH.S197604","DOI":"10.2147\/IJWH.S197604"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"[13] Tung KH, Goodman MT, Wu AH, McDuffie K, Wilkens LR, Kolonel LN, Nomura AM, Terada KY, Carney ME, Sobin LH. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol, 2003, 158(7):629-638. https:\/\/doi.org\/10.1093\/aje\/kwg177","DOI":"10.1093\/aje\/kwg177"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"[14] Mori M, Harabuchi I, Miyake H, Casagrande JT, Henderson BE, Ross RK. Reproductive, genetic, and dietary risk factors for ovarian cancer. Am J Epidemiol, 1988, 128(4):771-777. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a115030","DOI":"10.1093\/oxfordjournals.aje.a115030"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"[15] Kim SJ, Rosen B, Fan I, Ivanova A, McLaughlin JR, Risch H, Narod SA, Kotsopoulos J. Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer. Br J Cancer, 2017, 116(7):964-971. https:\/\/doi.org\/10.1038\/bjc.2017.35","DOI":"10.1038\/bjc.2017.35"},{"key":"ref15","unstructured":"[16] Salazar-Martinez E, Lazcano-Ponce EC, Gonzalez Lira-Lira G, Escudero-De los Rios P, Salmeron-Castro J, Hernandez-Avila M. Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico. Cancer Res, 1999, 59(15):3658-3662."},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"[17] Fathalla MF. Incessant ovulation - a factor in ovarian neoplasia? Lancet, 1971, 2(7716):163. https:\/\/doi.org\/10.1016\/s0140-6736(71)92335-X","DOI":"10.1016\/S0140-6736(71)92335-X"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"[18] Moorman PG, Schildkraut JM, Calingaert B, Halabi S, Vine MF, Berchuck A. Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States). Cancer Causes Control, 2002, 13(9):807-811. https:\/\/doi.org\/10.1023\/a:1020678100977","DOI":"10.1023\/A:1020678100977"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"[19] Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE, Morgan M, Schlesselman JJ. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology, 2000, 11(2):111-117. https:\/\/doi.org\/10.1097\/00001648-200003000-00006","DOI":"10.1097\/00001648-200003000-00006"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"[20] Jia D, Nagaoka Y, Katsumata M, Orsulic S. Inflammation is a key contributor to ovarian cancer cell seeding. Sci Rep, 2018, 8(1):12394. https:\/\/doi.org\/10.1038\/s41598-018-30261-8","DOI":"10.1038\/s41598-018-30261-8"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"[21] Sampson JA. Endometrial carcinoma of the ovary, arising in endometrial tissue in that organ. Arch Surg, 1925, 10(1):1-72. https:\/\/doi.org\/10.1001\/archsurg.1925.01120100007001","DOI":"10.1001\/archsurg.1925.01120100007001"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"[22] Chiang AJ, Chang C, Huang CH, Huang WC, Kan YY, Chen J. Risk factors in progression from endometriosis to ovarian cancer: a cohort study based on medical insurance data. J Gynecol Oncol, 2018, 29(3):e28. https:\/\/doi.org\/10.3802\/jgo.2018.29.e28","DOI":"10.3802\/jgo.2018.29.e28"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"[23] Pavone ME, Lyttle BM. Endometriosis and ovarian cancer: links, risks, and challenges faced. Int J Womens Health, 2015, 7:663-672. https:\/\/doi.org\/10.2147\/IJWH.S66824","DOI":"10.2147\/IJWH.S66824"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"[24] Sieh W, Salvador S, McGuire V, Weber RP, Terry KL, Rossing MA, Risch H, Wu AH, Webb PM, Moysich K, Doherty JA, Felberg A, Miller D, Jordan SJ; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group; Goodman MT, Lurie G, Chang-Claude J, Rudolph A, Kj\u00e6r SK, Jensen A, H\u00f8gdall E, Bandera EV, Olson SH, King MG, Rodriguez-Rodriguez L, Kiemeney LA, Marees T, Massuger LF, van Altena AM, Ness RB, Cramer DW, Pike MC, Pearce CL, Berchuck A, Schildkraut JM, Whittemore AS; Ovarian Cancer Association Consortium. Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. Int J Epidemiol, 2013, 42(2):579-589. https:\/\/doi.org\/10.1093\/ije\/dyt042","DOI":"10.1093\/ije\/dyt042"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"[25] Madsen C, Baandrup L, Dehlendorff C, Kjaer SK. Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study. Acta Obstet Gynecol Scand, 2015, 94(1):86-94. https:\/\/doi.org\/10.1111\/aogs.12516","DOI":"10.1111\/aogs.12516"},{"issue":"1","key":"ref25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0015-0282(16)58020-0","article-title":"Human menopausal gonadotropin and the risk of epithelial ovarian cancer","volume":"65","author":"Shushan","year":"1996","unstructured":"[26] Shushan A, Paltiel O, Iscovich J, Elchalal U, Peretz T, Schenker JG. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril, 1996, 65(1):13-18.","journal-title":"Fertil Steril"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"[27] Goodman MT, Wu AH, Tung KH, McDuffie K, Kolonel LN, Nomura AM, Terada K, Wilkens LR, Murphy S, Hankin JH. Association of dairy products, lactose, and calcium with the risk of ovarian cancer. Am J Epidemiol, 2002, 156(2):148-157. https:\/\/doi.org\/10.1093\/aje\/kwf022","DOI":"10.1093\/aje\/kwf022"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"[28] Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Persson IR. Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol, 2001, 83(3):575-585. https:\/\/doi.org\/10.1006\/gyno.2001.6451","DOI":"10.1006\/gyno.2001.6451"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"[29] Toss A, Tomasello C, Razzaboni E, Contu G, Grandi G, Cagnacci A, Schilder RJ, Cortesi L. Hereditary ovarian cancer: not only BRCA 1 and 2 genes. Biomed Res Int, 2015, 2015:341723. https:\/\/doi.org\/10.1155\/2015\/341723","DOI":"10.1155\/2015\/341723"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"[30] Nakamura K, Banno K, Yanokura M, Iida M, Adachi M, Masuda K, Ueki A, Kobayashi Y, Nomura H, Hirasawa A, Tominaga E, Aoki D. Features of ovarian cancer in Lynch syndrome (Review). Mol Clin Oncol, 2014, 2(6):909-916. https:\/\/doi.org\/10.3892\/mco.2014.397","DOI":"10.3892\/mco.2014.397"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"[31] Lu KH, Daniels M. Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention. Fam Cancer, 2013, 12(2):273-277. https:\/\/doi.org\/10.1007\/s10689-013-9664-5","DOI":"10.1007\/s10689-013-9664-5"},{"issue":"9","key":"ref31","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1158\/1055-9965.1521.13.9","article-title":"A case-control study of diet and the risk of ovarian cancer","volume":"13","author":"SY","year":"2004","unstructured":"[32] Pan SY, Ugnat AM, Mao Y, Wen SW, Johnson KC; Canadian Cancer Registries Epidemiology Research Group. A case-control study of diet and the risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev, 2004, 13(9):1521-1527.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"[33] Singh N, McCluggage WG, Gilks CB. High-grade serous carcinoma of tubo-ovarian origin: recent developments. Histopathology, 2017, 71(3):339-356. https:\/\/doi.org\/10.1111\/his.13248","DOI":"10.1111\/his.13248"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"[34] Chen S, Li Y, Qian L, Deng S, Liu L, Xiao W, Zhou Y. A review of the clinical characteristics and novel molecular subtypes of endometrioid ovarian cancer. Front Oncol, 2021, 11:668151. https:\/\/doi.org\/10.3389\/fonc.2021.668151","DOI":"10.3389\/fonc.2021.668151"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"[35] Fujiwara K, Shintani D, Nishikawa T. Clear-cell carcinoma of the ovary. Ann Oncol, 2016, 27(Suppl 1):i50-i52. https:\/\/doi.org\/10.1093\/annonc\/mdw086","DOI":"10.1093\/annonc\/mdw086"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"[36] Otsuka I, Matsuura T. Screening and prevention for high-grade serous carcinoma of the ovary based on carcinogenesis-fallopian tube- and ovarian-derived tumors and incessant retrograde bleeding. Diagnostics (Basel), 2020, 10(2):120. https:\/\/doi.org\/10.3390\/diagnostics10020120","DOI":"10.3390\/diagnostics10020120"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"[37] Hong MK, Chu TY, Ding DC. The fallopian tube is the culprit and an accomplice in type II ovarian cancer: a review. Tzu Chi Med J, 2013, 25(4):203-205. https:\/\/doi.org\/10.1016\/j.tcmj.2013.04.002","DOI":"10.1016\/j.tcmj.2013.04.002"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"[38] Kim J, Park EY, Kim O, Schilder JM, Coffey DM, Cho CH, Bast RC Jr. Cell origins of high-grade serous ovarian cancer. Cancers (Basel), 2018, 10(11):433. https:\/\/doi.org\/10.3390\/cancers10110433","DOI":"10.3390\/cancers10110433"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"[39] Horta M, Cunha TM. Sex cord-stromal tumors of the ovary: a comprehensive review and update for radiologists. Diagn Interv Radiol, 2015, 21(4):277-286. https:\/\/doi.org\/10.5152\/dir.2015.34414","DOI":"10.5152\/dir.2015.34414"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"[40] Al Harbi R, McNeish IA, El-Bahrawy M. Ovarian sex cord-stromal tumors: an update on clinical features, molecular changes, and management. Int J Gynecol Cancer, 2021, 31(2):161-168. https:\/\/doi.org\/10.1136\/ijgc-2020-002018","DOI":"10.1136\/ijgc-2020-002018"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"[41] Ray-Coquard I, Brown J, Harter P, Provencher DM, Fong PC, Maenpaa J, Ledermann JA, Emons G, Rigaud DB, Glasspool RM, Mezzanzanica D, Colombo N. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors. Int J Gynecol Cancer, 2014, 24(9 Suppl 3):S42-S47. https:\/\/doi.org\/10.1097\/IGC.0000000000000249","DOI":"10.1097\/IGC.0000000000000249"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"[42] Kaur B. Pathology of malignant ovarian germ cell tumours. Diagn Histopathol, 2020, 26(6):289-297. https:\/\/doi.org\/10.1016\/j.mpdhp.2020.03.006","DOI":"10.1016\/j.mpdhp.2020.03.006"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"[43] Shaaban AM, Rezvani M, Elsayes KM, Baskin H Jr, Mourad A, Foster BR, Jarboe EA, Menias CO. Ovarian malignant germ cell tumors: cellular classification and clinical and imaging features. Radiographics, 2014, 34(3):777-801. https:\/\/doi.org\/10.1148\/rg.343130067","DOI":"10.1148\/rg.343130067"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"[44] Zhou L, Yao L, Dai L, Zhu H, Ye X, Wang S, Cheng H, Ma R, Liu H, Cui H, Chang X. Ovarian endometrioid carcinoma and clear cell carcinoma: a 21-year retrospective study. J Ovarian Res, 2021, 14(1):63. https:\/\/doi.org\/10.1186\/s13048-021-00804-1","DOI":"10.1186\/s13048-021-00804-1"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"[45] Cybulska P, Paula ADC, Tseng J, Leitao MM Jr, Bashashati A, Huntsman DG, Nazeran TM, Aghajanian C, Abu-Rustum NR, DeLair DF, Shah SP, Weigelt B. Molecular profiling and molecular classification of endometrioid ovarian carcinomas. Gynecol Oncol, 2019, 154(3):516-523. https:\/\/doi.org\/10.1016\/j.ygyno.2019.07.012","DOI":"10.1016\/j.ygyno.2019.07.012"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"[46] Reichenbach J, Schmoeckel E, Mahner S, Trillsch F. Diagnostic workup for endometrioid borderline ovarian tumors (eBOT) requires histopathological evaluation of the uterus. J Ovarian Res, 2021, 14(1):89. https:\/\/doi.org\/10.1186\/s13048-021-00839-4","DOI":"10.1186\/s13048-021-00839-4"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"[47] Tong HC, Li YC, Li LY, Xu HT, Ma S, Zhang WL, Wildes T, Yang LH, Wang E. Endometrioid adenofibroma of ovary: a case report and review of literature. Medicine (Baltimore), 2023, 102(8):e32965. https:\/\/doi.org\/10.1097\/MD.0000000000032965","DOI":"10.1097\/MD.0000000000032965"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"[48] Hauptmann S, Friedrich K, Redline R, Avril S. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch, 2017, 470(2):125-142. https:\/\/doi.org\/10.1007\/s00428-016-2040-8","DOI":"10.1007\/s00428-016-2040-8"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"[49] Morice P, Uzan C, Fauvet R, Gouy S, Duvillard P, Darai E. Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet Oncol, 2012, 13(3):e103-e115. https:\/\/doi.org\/10.1016\/S1470-2045(11)70288-1","DOI":"10.1016\/S1470-2045(11)70288-1"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"[50] Trillsch F, Ruetzel JD, Herwig U, Doerste U, Woelber L, Grimm D, Choschzick M, Jaenicke F, Mahner S. Surgical management and perioperative morbidity of patients with primary borderline ovarian tumor (BOT). J Ovarian Res, 2013, 6(1):48. https:\/\/doi.org\/10.1186\/1757-2215-6-48","DOI":"10.1186\/1757-2215-6-48"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"[51] Colombo N, Sessa C, Bois AD, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, Baert T, Belaroussi I, Dashora A, Olbrecht S, Planchamp F, Querleu D; ESMO-ESGO Ovarian Cancer Consensus Conference Working Group. ESMO-ESGO Consensus Conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer, 2019, 29(4):728-760. https:\/\/doi.org\/10.1136\/ijgc-2019-000308","DOI":"10.1136\/ijgc-2019-000308"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"[52] Jia SZ, Zhang JJ, Yang JJ, Xiang Y, Liang Z, Leng JH. Risk of synchronous endometrial disorders in women with endometrioid borderline tumors of the ovary. J Ovarian Res, 2018, 11(1):30. https:\/\/doi.org\/10.1186\/s13048-018-0405-0","DOI":"10.1186\/s13048-018-0405-0"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"[53] Yokoyama Y, Moriya T, Takano T, Shoji T, Takahashi O, Nakahara K, Yamada H, Yaegashi N, Okamura K, Izutsu T, Sugiyama T, Tanaka T, Kurachi H, Sato A, Tase T, Mizunuma H. Clinical outcome and risk factors for recurrence in borderline ovarian tumours. Br J Cancer, 2006, 94(11):1586-1591. https:\/\/doi.org\/10.1038\/sj.bjc.6603139","DOI":"10.1038\/sj.bjc.6603139"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"[54] Seong SJ, Kim DH, Kim MK, Song T. Controversies in borderline ovarian tumors. J Gynecol Oncol, 2015, 26(4):343-349. https:\/\/doi.org\/10.3802\/jgo.2015.26.4.343","DOI":"10.3802\/jgo.2015.26.4.343"},{"key":"ref54","unstructured":"[55] World Health Organization (WHO) Classification of Tumours Editorial Board. Female genital tumours. 5th edition, vol. 4, WHO Classification of Tumours, International Agency for Research on CANCER (IARC) Press, Lyon, France, 2020, 1-632."},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"[56] Watanabe H, Harada N, Nobuhara I, Haruta N, Higashiura Y, Watanabe S. Magnetic resonance imaging and flexible hysterofiberscopic findings of a uterine adenofibroma: case report and literature review. Case Rep Obstet Gynecol, 2018, 2018:9685683. https:\/\/doi.org\/10.1155\/2018\/9685683","DOI":"10.1155\/2018\/9685683"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"[57] Ra JC, Park SB, Lee JB, Han BH, Lee YH, Hong SR. Adenofibroma in the uterine cervix manifesting as multilocular cystic lesions. Ultrasound Q, 2017, 33(1):74-76. https:\/\/doi.org\/10.1097\/RUQ.0000000000000242","DOI":"10.1097\/RUQ.0000000000000242"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"[58] Taylor EC, Irshaid L, Mathur M. Multimodality imaging approach to ovarian neoplasms with pathologic correlation. Radiographics, 2021, 41(1):289-315. https:\/\/doi.org\/10.1148\/rg.2021200086","DOI":"10.1148\/rg.2021200086"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"[59] Jain D, Siraj F, Aggarwal N. Endometrioid adenofibroma arising in an endometriotic cyst. J Obstet Gynaecol, 2011, 31(4):352-354. https:\/\/doi.org\/10.3109\/01443615.2011.562333","DOI":"10.3109\/01443615.2011.562333"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"[60] Mondal SK, Banyopadhyay R, Nag DR, Roychowdhury S, Mondal PK, Sinha SK. Histologic pattern, bilaterality and clinical evaluation of 957 ovarian neoplasms: a 10-year study in a tertiary hospital of eastern India. J Cancer Res Ther, 2011, 7(4):433-437. https:\/\/doi.org\/10.4103\/0973-1482.92011","DOI":"10.4103\/0973-1482.92011"},{"issue":"4","key":"ref60","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/(SICI)1097-0142(19990215)85:4<905::AID-CNCR19>3.0.CO;2-8","article-title":"The current status of surgical staging of ovarian serous borderline tumors","volume":"85","author":"Lin","year":"1999","unstructured":"[61] Lin PS, Gershenson DM, Bevers MW, Lucas KR, Burke TW, Silva EG. The current status of surgical staging of ovarian serous borderline tumors. Cancer, 1999, 85(4):905-911.","journal-title":"Cancer"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"[62] Morice P. Borderline tumours of the ovary and fertility. Eur J Cancer, 2006, 42(2):149-158. https:\/\/doi.org\/10.1016\/j.ejca.2005.07.029","DOI":"10.1016\/j.ejca.2005.07.029"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"[63] Matsuki M, Numoto I, Suzuki A, Hamakawa T, Matsukubo Y, Tsurusaki M, Ishii K, Otani T, Matsumura N. Magnetic resonance imaging of recurrent adult granulosa cell tumor of the ovary: a retrospective analysis of 11 cases. J Comput Assist Tomogr, 2020, 44(6):887-892. https:\/\/doi.org\/10.1097\/RCT.0000000000001096","DOI":"10.1097\/RCT.0000000000001096"},{"key":"ref63","unstructured":"[64] Tenea Cojan TS, Vidrighin CD, Ciobanu M, Paun I, Teodorescu M, Mogos G, Tenovici M, Florescu M, Mogos D. Breast-conserving surgery in breast cancer. Chirurgia (Bucharest), 2012, 107(5):616-625."},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"[65] Poncelet C, Fauvet R, Boccara J, Dara\u00ef E. Recurrence after cystectomy for borderline ovarian tumors: results of a French multicenter study. Ann Surg Oncol, 2006, 13(4):565-571. https:\/\/doi.org\/10.1245\/ASO.2006.12.024","DOI":"10.1245\/ASO.2006.12.024"},{"key":"ref65","unstructured":"[66] Lim-Tan SK, Cajigas HE, Scully RE. Ovarian cystectomy for serous borderline tumors: a follow-up study of 35 cases. Obstet Gynecol, 1988, 72(5):775-781."},{"key":"ref66","unstructured":"[67] Trop\u00e9 C, Davidson B, Paulsen T, Abeler VM, Kaern J. Diagnosis and treatment of borderline ovarian neoplasms \"the state of the art\". Eur J Gynaecol Oncol, 2009, 30(5):471-482."},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"[68] Burger CW, Prinssen HM, Baak JPA, Wagenaar N, Kenemans P. The management of borderline epithelial tumors of the ovary. Int J Gynecol Cancer, 2000, 10(3):181-197. https:\/\/doi.org\/10.1046\/j.1525-1438.2000.010003181.x","DOI":"10.1046\/j.1525-1438.2000.010003181.x"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"[69] du Bois A, Ewald-Riegler N, du Bois O, Harter P. Borderline-Tumoren des Ovars - eine systematische \u00dcbersicht [Borderline tumors of the ovary: a systematic review]. Geburtshilfe Frauenheilkd, 2009, 69(9):807-833. https:\/\/doi.org\/10.1055\/s-0029-1186007","DOI":"10.1055\/s-0029-1186007"},{"key":"ref69","unstructured":"[70] Eremia IA, Ciobanu M, Tenea T, Com\u0103nescu MV, Cr\u0103i\u0163oiu S. Invasive papillary carcinoma of the mammary gland: histopathologic and immunohistochemical aspects. Rom J Morphol Embryol, 2012, 53(3 Suppl):811-815."},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"[71] Nakagawa E, Abiko K, Kido A, Kitamura S, Yamaguchi K, Baba T, Minamiguchi S, Matsumura N. Four cases of endometrioid borderline ovarian tumour: case reports and literature review. BJR Case Rep, 2017, 4(1):20170062. https:\/\/doi.org\/10.1259\/bjrcr.20170062","DOI":"10.1259\/bjrcr.20170062"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"[72] van Leeuwen FE, Klip H, Mooij TM, van de Swaluw AMG, Lambalk CB, Kortman M, Laven JSE, Jansen CAM, Helmerhorst FM, Cohlen BJ, Willemsen WNP, Smeenk JMJ, Simons AHM, van der Veen F, Evers JLH, van Dop PA, Macklon NS, Burger CW. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod, 2011, 26(12):3456-3465. https:\/\/doi.org\/10.1093\/humrep\/der322","DOI":"10.1093\/humrep\/der322"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"[73] Fauvet R, Poncelet C, Boccara J, Descamps P, Fondrinier E, Dara\u00ef E. Fertility after conservative treatment for borderline ovarian tumors: a French multicenter study. Fertil Steril, 2005, 83(2):284-290; quiz 525-526. https:\/\/doi.org\/10.1016\/j.fertnstert.2004.10.009","DOI":"10.1016\/j.fertnstert.2004.10.009"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"[74] En\u0103tescu VR, Kalinovi\u0107 R, Vlad G, Nussbaum LA, Hogea L, En\u0103tescu I, Marinescu I, Ifteni P, Simu M, Marian C, Giurgi-Oncu C, Papav\u0103 I. The presence of peripheral inflammatory markers in patients with major depressive disorder, the associated symptoms profiles and the antidepressant efficacity of Celecoxib. Farmacia, 2020, 68(3):483-491. https:\/\/doi.org\/10.31925\/farmacia.2020.3.14","DOI":"10.31925\/farmacia.2020.3.14"},{"key":"ref74","unstructured":"[75] Bondoc EN, Marinescu D, Marinescu I, M\u0103lin RD, Stanca L, Z\u0103voi RE. Current understanding of psycho-neurobiology in depressive disorders with suicidal thoughts - translational models. Rom J Morphol Embryol, 2019, 60(2):389-402.\""}],"container-title":["Romanian Journal of Morphology and Embryology"],"original-title":[],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T08:45:33Z","timestamp":1748594733000},"score":1,"resource":{"primary":{"URL":"https:\/\/rjme.ro\/archive\/66\/1\/3\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,5,15]]},"published-print":{"date-parts":[[2025,5,23]]}},"URL":"https:\/\/doi.org\/10.47162\/rjme.66.1.03","relation":{},"ISSN":["1220-0522","2066-8279"],"issn-type":[{"value":"1220-0522","type":"print"},{"value":"2066-8279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]}}}